International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(8), P. 4511 - 4511
Published: April 20, 2024
Major
depressive
disorder
is
a
severe
mood
associated
with
marked
decrease
in
quality
of
life
and
social
functioning,
accompanied
by
risk
suicidal
behavior.
Therefore,
seeking
out
adhering
to
effective
treatment
great
personal
society-wide
importance.
Weight
changes
antidepressant
therapy
are
often
cited
as
the
reason
for
withdrawal
thus
an
important
topic
interest.
There
indeed
exists
significant
mechanistic
overlap
between
depression,
treatment,
regulation
appetite
body
weight.
The
suggested
pathomechanisms
include
abnormal
functioning
homeostatic
(mostly
humoral)
hedonic
dopaminergic)
circuits
regulation,
well
causing
neuromorphological
neurophysiological
underlying
development
disorder.
However,
this
issue
still
extensively
discussed.
This
review
aims
summarize
mechanisms
linked
depression
context
weight
change.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1389 - 1389
Published: May 3, 2024
Probiotics
may
represent
a
safe
and
easy-to-use
treatment
option
for
depression
or
its
metabolic
comorbidities.
However,
it
is
not
known
whether
features
can
influence
the
efficacy
of
probiotics
treatments
depression.
This
trial
involved
parallel-group,
prospective,
randomized,
double-blind,
controlled
design.
In
total,
116
participants
with
received
probiotic
preparation
containing
Lactobacillus
helveticus
Rosell®-52
Bifidobacterium
longum
Rosell®-175
placebo
over
60
days.
The
psychometric
data
were
assessed
longitudinally
at
five
time-points.
Data
blood
pressure,
body
weight,
waist
circumference,
complete
count,
serum
levels
C-reactive
protein,
cholesterol,
triglycerides,
fasting
glucose
measured
beginning
intervention
period.
There
was
no
advantage
usage
in
score
overall
(PRO
vs.
PLC:
F(1.92)
=
0.58;
p
0.45).
we
found
higher
rate
minimum
clinically
important
differences
patients
supplemented
than
those
allocated
to
generally
(74.5
53.5%;
X2(1,n
94)
4.53;
0.03;
NNT
4.03),
as
well
antidepressant-treated
subgroup.
Moreover,
that
more
advanced
pre-intervention
abnormalities
(such
overweight,
excessive
central
adipose
tissue,
liver
steatosis),
lower
improvements
scores.
A
baseline
stress
level
correlated
better
improvements.
current
formulations
only
be
used
complementary
depressive
disorders.
Metabolic
require
complex
treatments.
ClinicalTrials.gov
identifier:
NCT04756544.
Letters in Applied Microbiology,
Journal Year:
2024,
Volume and Issue:
77(7)
Published: July 1, 2024
Sleeplessness
(insomnia)
is
a
potential
symptom
of
depression.
A
probiotic
NVP1704
alleviates
depression-like
behavior
and
neuroinflammation
in
mice.
Therefore,
to
understand
whether
could
be
effective
against
sleeplessness
vivo,
we
exposed
immobilization
stress
(IS)
mice,
then
orally
administered
for
5
days,
assayed
depression/anxiety-like
the
open
field,
elevated
plus
maze,
tail
suspension
tests,
sleeping
latency
time,
sleep
duration,
euthanized
by
exposure
CO2,
analyzed
their
related
biomarkers.
Oral
administration
decreased
IS-induced
time
increased
IS-suppressed
duration.
expression
γ-aminobutyric
acid
(GABA),
GABAA
receptor
α1
(GABAARα1)
α2
subunits
(GABAARα2),
serotonin,
5-HT
receptors
(5-HT1AR
5-HT1BR),
melatonin
(MT1R
MT2R)
prefrontal
cortex
thalamus.
also
GABAARα1-positive
cell
population
corticosterone,
TNF-α,
IL-6
NF-κB+Iba1+
brain
myeloperoxidase,
NF-κB+CD11c+
colon.
Based
on
these
findings,
may
alleviate
depression/anxiety/sleeplessness-like
behaviors
through
upregulation
serotonergic
GABAergic
systems
downregulation
NF-κB
activation.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(21), P. 3711 - 3711
Published: Oct. 30, 2024
Insomnia
(sleeplessness)
is
a
potential
symptom
of
stress-induced
depression/anxiety
(DA),
which
induces
TNF-α
expression.
Therefore,
this
study
aimed
to
examine
the
effect
Frontiers in Psychiatry,
Journal Year:
2024,
Volume and Issue:
15
Published: Nov. 5, 2024
Major
depressive
disorder
(MDD)
and
bipolar
(BD)
are
two
of
the
most
prevalent
mood
disorders
that
seriously
jeopardize
both
physical
mental
health.
The
current
diagnosis
MDD
BD
relies
primarily
on
clinical
symptoms.
However,
correctly
differentiating
between
during
episode
states
remains
a
substantial
challenge.
human
gut
hosts
large
diverse
microbiota,
which
plays
pivotal
role
in
various
physiological
processes.
Emerging
evidence
suggests
microbiota
(GM)
exerts
beneficial
effects
health
disorders,
including
MDD,
BD,
schizophrenia,
through
microbe-gut-brain
axis
(MGBA).
In
recent
years,
relationship
GM
has
garnered
considerable
attention,
leading
to
intensive
research
this
area.
MGBA
is
bidirectional
communication
system
brain.
Growing
indicates
brain
can
influence
GM,
turn
may
modulate
axis.
This
review
aims
explore
changes
patients
with
evaluate
different
treatments
their
medication,
probiotic,
prebiotic
synbiotic
interventions,
fecal
transplantation
(FMT).
By
doing
so,
we
seek
identify
potential
disease-specific
biomarkers,
improve
differential
diagnosis,
offer
novel
therapeutic
avenues
for
these
disorders.
Frontiers in Microbiology,
Journal Year:
2024,
Volume and Issue:
15
Published: July 3, 2024
The
role
of
the
gut
microbiota
in
pathophysiology
depression
has
been
explored
numerous
studies,
which
have
confirmed
that
baseline
microbial
profiles
patients
with
differ
from
those
healthy
individuals.
microbiome
affects
metabolic
activity
immune
and
central
nervous
systems
regulates
intestinal
ecology
through
neuroendocrine
system.
Additionally,
changes
differed
among
who
demonstrated
varying
treatment
response.
Currently,
probiotics
are
an
emerging
for
depression;
however,
efficacy
modulating
remains
uncertain.
mechanisms
by
affect
response
remain
unclear.
In
this
review,
we
aimed
to
summarize
differences
between
remission
non-remission
groups
after
antidepressant
therapy.
summarized
possible
may
contribute
resistance
effects
on
systems,
various
enzymes,
bioaccumulation,
blood–brain
barrier,
provide
a
basis
treating
targeting
microbiota.
